Atea Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-03-09$6.15 RISE2026-05-15$4.10 PEAK2026-05-28$4.73 80d | -33.3% 67d | Missed | Missed | — | — | +15.4% 13d | Missed |
DROP2025-07-25$3.90 RISE2025-11-14$2.96 PEAK2026-02-11$4.46 201d | -24.1% 112d | Missed | Missed | — | — | +50.7% 89d | Missed |
DROP2025-07-25$3.90 RISE2025-10-02$2.82 PEAK2025-12-26$3.65 154d | -27.7% 69d | Missed | Missed | — | — | +29.4% 85d | Missed |
DROP2025-01-03$3.52 RISE2025-05-14$2.55 PEAK2025-07-25$3.90 203d | -27.6% 131d | Missed | Missed | — | — | +52.9% 72d | Missed |
DROP2025-01-03$3.52 RISE2025-04-08$2.65 PEAK2025-07-03$3.74 181d | -24.7% 95d | Missed | Missed | — | — | +41.1% 86d | Missed |
DROP2024-09-17$4.02 RISE2024-12-13$2.93 PEAK2025-01-03$3.52 108d | -27.1% 87d | Missed | Missed | — | — | +20.1% 21d | Missed |
DROP2024-09-17$4.02 RISE2024-12-05$2.93 PEAK2025-01-03$3.52 108d | -27.1% 79d | Missed | Missed | — | — | +20.1% 29d | Missed |
DROP2024-03-01$4.45 RISE2024-07-10$3.17 PEAK2024-09-17$4.02 200d | -28.8% 131d | Missed | Missed | — | — | +26.8% 69d | Missed |
DROP2023-07-18$3.70 RISE2023-11-22$2.80 PEAK2024-02-20$4.33 217d | -24.3% 127d | Missed | Missed | — | — | +54.6% 90d | Missed |
DROP2022-11-15$5.18 RISE2023-03-24$3.00 PEAK2023-05-22$5.06 188d | -42.1% 129d | Missed | Missed | — | — | +68.7% 59d | Missed |
DROP2022-05-27$8.18 RISE2022-06-16$6.34 PEAK2022-08-05$8.79 70d | -22.5% 20d | Missed | Missed | — | — | +38.6% 50d | Missed |
DROP2022-01-03$9.19 RISE2022-05-09$5.33 PEAK2022-07-13$8.49 191d | -42.0% 126d | Missed | Missed | — | — | +59.3% 65d | Missed |
DROP2021-11-03$11.99 RISE2022-03-14$5.50 PEAK2022-05-27$8.18 205d | -54.1% 131d | Missed | Missed | — | — | +48.7% 74d | Missed |
DROP2021-10-04$44.59 RISE2021-11-23$7.67 PEAK2021-12-27$9.43 84d | -82.8% 50d | Missed | Missed | — | — | +22.9% 34d | Missed |
DROP2021-08-11$33.01 RISE2021-09-15$25.98 PEAK2021-10-04$44.59 54d | -21.3% 35d | Missed | Missed | — | — | +71.6% 19d | Missed |
1–15 / 17 1 / 2 | |||||||
Atea Pharmaceuticals, Inc. gets a Buy ahead of mid-2026 phase 3 HCV data. Click here to read in detail about the AVIR stock.
Over the last 7 days, the market has risen 1.1%, with a notable 29% increase over the past year and earnings projected to grow by 17% annually. While penny stocks might seem like a term from bygone market eras, they continue to offer intriguing opportunities for investors seeking affordability and growth potential in smaller or newer companies. In this article, we explore three penny stocks that stand out for their financial strength and potential for long-term success amidst current market...
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Moby summary of Atea Pharmaceuticals, Inc.'s Q1 2026 earnings call
BOSTON, May 13, 2026 -- Atea Pharmaceuticals, Inc. , a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral...
Atea Pharmaceuticals Inc (AVIR) showcases robust financial health and strategic pipeline expansion, while navigating competitive pressures and global healthcare challenges.
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call May 12, 2026 4:30 PM EDTCompany ParticipantsJonae Barnes - Senior Vice President of Investor...
Presentation Operator MessageOperator Ladies and gentlemen, thank you for standing by. Welcome to Atea Pharmaceuticals First Quarter 2026 Earnings Conference Call. [Operator Instructions] I will
Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no approved treatment options. During the company’s first-quarter 2026 earnings call, Chief Executive Off
2026-05-12. The following slide deck was published by Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals Q1 loss of $0.57 per share beat estimates, with no revenue. Focus remains on pivotal Phase 3 HCV data readouts mid and late 2026.
Atea Pharmaceuticals Inc: Atea Pharmaceuticals reports first quarter 2026 financial results and provides business update...
Q1 2026 Financial and Business Update May 12, 2026 Focused Antiviral Pipeline with De-risked Phase 3 Program ...
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.59) by 3.39 percent. This is a 42.5 percent decrease over losses of $(0.40) per share
BOSTON, May 05, 2026 -- Atea Pharmaceuticals, Inc. , a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral...
Momentum warning for health care sector stocks: RSI indicator shows overbought assets. Arcellx (ACLX) and Atea Pharma (AVIR) among top-ranked.
Evercore ISI Group analyst Jonathan Miller maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Outperform and raises the price target from $6 to $10.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AVIR | -16.31% | -4.11% | +30.81% | +57.24% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -19.28% | +1.61% | +34.26% | +44.55% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 11.95M | $64.30M | 0.00% | Added+23.5% | 2026-03-31 |
| TwoSigma | quant | 1.86M | $10.03M | 0.01% | Added+150.1% | 2026-03-31 |
| StateStreet | passive | 1.69M | $9.12M | 0.00% | Trimmed-5.0% | 2026-03-31 |
| RenTech | quant | 1.17M | $6.28M | 0.01% | Trimmed-1.9% | 2026-03-31 |
| DEShaw | quant | 379.3K | $2.04M | 0.00% | Trimmed-18.4% | 2026-03-31 |
| Citadel | multi-strat | 119.6K | $643.20K | 0.00% | Added+87.1% | 2026-03-31 |
| Wellington | fundamental | 57.0K | $306.71K | 0.00% | Trimmed-76.5% | 2026-03-31 |
| TRowePrice | fundamental | 106.6K | $574 | 0.00% | Added+9.5% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.56 | — | — |
| 2026-03-05 | -0.48 | -0.57 | -17.53% |
| 2025-11-12 | -0.41 | -0.53 | -27.71% |
| 2025-08-07 | -0.45 | -0.44 | +2.22% |
| 2025-05-12 | -0.41 | -0.40 | +2.61% |
| 2025-03-06 | -0.29 | -0.40 | -38.11% |
| 2024-11-07 | -0.43 | -0.37 | +13.02% |
| 2024-08-07 | -0.77 | -0.48 | +37.35% |
| 2024-05-14 | -0.61 | -0.75 | -23.81% |
| 2024-02-28 | -0.50 | -0.47 | +5.37% |
| 2023-11-08 | -0.46 | -0.40 | +13.50% |
| 2023-08-08 | -0.47 | -0.34 | +27.64% |
| 2023-05-08 | -0.48 | -0.43 | +9.94% |
| 2023-02-28 | -0.45 | -0.41 | +9.03% |
| 2022-11-07 | -0.44 | -0.10 | +77.43% |
| 2022-08-08 | -0.49 | -0.38 | +22.71% |